For Researchers

Today’s research leads to tomorrow’s breakthroughs.

Join our mailing list for AFTD Research news and funding opportunities

Previous Grant Recipients

Pilot Grant Recipients

Name & Institution Title Amount Category
2023
Daniel Mordes
UCSF		 Defining the role of TBK1 loss-of-function in FTD $110,000 Pathways for Hope
Steven Boeynaems
Baylor College of Medicine		 Aberrant protein condensation as a driver of neuroinflammation in ALS/FTD $110,000 Pathways for Hope
2022
Aaron Burberry, PhD
Case Western Reserve University		 Bacterial triggers of neural inflammation in C9ORF72-FTD locus $60,000 Pathways for Hope
Meysam Yazdankhah, PhD
Regenerative Research Foundation		 Co-promoting autophagy and proteasome function to lower tau in FTD neurons $60,000 Pathways for Hope
2021
Andrew Arrant, PhD
University of Alabama at Birmingham		 Investigating the role of lysosomal progranulin in FTD locus $60,000 Basic Science
Allison Lindauer, PhD
Oregon Health & Science University		 STELLA-FTD: using technology to support FTD caregivers $59,689 Well-Being in FTD
Maria Catarina Silva, PhD
Massachusetts General Hospital		 Mechanisms of AMPK-mediated rescue of tauopathy in human FTD neuronal models $60,000 Basic Science
2020
David Butler, PhD
Regenerative Research Foundation		 Optimization of bifunctional anti-tau intracellular antibody delivery into human neurons locus $60,000 Susan Marcus Translational Research
2019
Linda Wilson, PhD
Drexel University		 Improving the ability of family caregivers to care for persons living with frontotemporal dementia through an innovative simulation program $60,000 Nonpharmacological Therapies and Tools
2018
Paschalis Kratsios, PhD
University of Chicago		 A C. elegans model to study the disease- producing effects of dipeptide repeats from the C9ORF72 locus $60,000 Basic Science
Liam Chen, MD, PhD
Johns Hopkins University		 Identification of target genes regulated by TDP-43 in human FTD brains $60,000 Susan Marcus Translational Research
Lauren Massimo, PhD, CRNP
University of Pennsylvania School of Nursing		 Development of a goal-directed behavior app: Changing apathyinto action in frontotemporal degeneration $60,000 Nonpharmacological Therapies and Tools
2017
Todd Cohen, PhD
University of North Carolina – Chapel Hill		 Accelerated tau pathogenesis in a new mouse model of frontotemporal dementia $60,000 Basic Science
Haakon Nygaard, MD
University of British Columbia		 Ambulatory assessment of sleep disorders in frontotemporal dementia $60,000 Clinical Research
2016
Maria Llorens-Martín, PhD
CIBERNED		 Tau and adult neurogenesis. Therapeutic potential for frontotemporal degeneration $60,000 Basic Science
Paola Caroppo, MD, PhD
IRCCS Foundation Carlo Besta Neurological Institute		 Detection of misfolded TDP-43 protein in CSF and plasma of GRN and C9orf72 mutation carriers $60,000 Clinical Research
2015
Sandra Almeida, PhD
University of Massachusetts		 Reducing repeat toxicity in iPSC-derived cortical neurons of C9ORF72 FTD patients $60,000 Basic Science
Roy Hamilton, MD
University of Pennsylvania		 Transcranial direct current stimulation (tDCS) as a treatment for primary progressive aphasia $60,000 Clinical Research
2014*
Thomas Kukar, PhD
Emory University		 Identification of the signaling receptor that mediates the neurotrophic activity of progranulin (PGRN) $60,000 Basic Science
Jennifer Yokoyama, PhD
UCSF		 RNA signatures of frontotemporal dementia and ALS due to C9ORF72 expansion $60,000 Clinical Research
2013
Emily Rogalski, PhD
Northwestern University		 Internet-based speech therapy: Improving quality of life and access to care $60,000 -
2012
No award
2011
Fenghua Hu, PhD
Cornell University		 Signaling mechanisms of progranulin $60,000 -
2010
Stephen Strittmatter, MD
Yale University		 Imaging the role of progranulin interaction with sortilin in frontotemporal lobar degeneration  $60,000 -
Stephanie Cosentino, MD
Columbia University		 Early indicator and modifiers of age of onset in FTD $30,000 -
2009
John van Swieten, PhD
Erasmus Medical Center		 Resting-state functional MRI in presymptomatic mutation carriers of MAPT or PGRN mutation $60,000 -
2008
Mark Gluck, PhD
Rutgers University – Newark		 Insensitivity to negative (penalizing) feedback for inappropriate behaviors in FTD linked to orbito-frontal dysfunction $60,000 -
Rosa Rademakers, PhD
Mayo Clinic-Jacksonville		 MicroRNA dysregulation in frontotemporal lobar degeneration $60,000 -
2007
Marc Cruts, PhD
University of Antwerp		 Gene identification in a novel Mendelian FTLD-MND locus $60,000 -
J. Paul Taylor, MD
University of Pennsylvania		 Assessing the molecular genetics of TDP-43-related neurodegeneration using a Drosophila model $60,000 -
2006
Blair Leavitt, MD; Co-PI: Ian Mackenzie, MD
University of British Columbia		 Generation of a mouse model of familial FTD caused by progranulin mutations $50,000 -
2005
Eileen Biggio, MD
Northwestern University		 Ubiquitinated proteins found in the “inclusions” that characterize brain cells in FTLD-MND $35,000 -


*First year for independent awards in two categories: Basic Science and Clinical Research

Postdoctoral Fellowship Recipients

Name & Institution Title Amount Mentor
2020-2022
Eric Anderson, PhD
University of Pittsburgh		 Investigating O-glycosylation modification in C9ORF72 FTD/ALS pathogenesis $120,000
Daniel Okobi, MD, PhD
University of California, Los Angeles		 Neuronal network dysfunction in neurodegenerative disease $120,000
Hijai Regina Shin, PhD
University of California, Berkeley		 Dissecting the molecular consequences of C9orf72 loss in lysosomal homeostasis and ALS-FTD disease pathogenesis $120,000
Matthew Nolan, PhD
Massachusetts General Hospital		 Modulating TDP-43-dependent loss of STMN2 in FTD $120,000
Oriol Dols Icardo, PhD
Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau		 Identification of an RNA-based biomarker for FTD $110,000
2017 - 2019
Ming-Yuan Su, PhD
The Regents of the University of California		 A structural approach to rescuing C9orf72 haploinsufficiency in ALS/FTD $110,000
Kathryn Bowles, PhD
Icahn School of Medicine at Mt. Sinai		 Identification and validation of novel MAPT splicing factors and RNA-binding proteins $110,000 Alison Goate, PhD
Joseph-Patrick Clarke, PhD
University of Pittsburgh		 Nucleocytoplasmic transport defects perturb granular flux In FTD $110,000 Chris Donnelly, PhD
2015 - 2017
Hilary Archbold, PhD
University of Michigan		 RNA dysfunction in frontotemporal dementia $110,000 Sami Barmada, MD, PhD
Maya Lichtenstein, MD
University of British Columbia/Geisinger Health System		 Developing a risk assessment tool for discriminating social cognition deficits in behavioral variant frontotemporal dementia from that of depression $110,000 Howard Feldman, MD
2013 - 2015
M. Catarina Silva, PhD
MGH		 Chemical neurobiology of tauopathy patient ip sc-derived neurons $110,000 Stephen Haggarty, PhD
2011 - 2013
Alexandra Nicholson, PhD
Mayo Clinic-Jacksonville		 TMEM106B and related family members in progranulin biology $110,000 Rosa Rademakers, PhD
2009 - 2011
Todd Cohen, PhD
University of Pennsylvania		 TDP-43 acetylation and its link to frontotemporal dementia $110,000 Virginia M.-Y. Lee, PhD

AFTD-ADDF Accelerating Drug Discovery for FTD

Name Institution Title
2021
Anna Orr, PhD Cornell University Lead optimization of novel site-selective blockers of mitochondrial complex III ROS as FTD therapeutics
2018
Luana Fioriti Plico Biotech SUMO2 mimetics as innovative inhibtors of tau toxicity in pre-clinical models of frontotemproal dementia
John Kent Werner, MD, PhD Cogentis Therapeutics Preclinical pharmacokinetics and pharmacodynamics of CT-526 in the tauopathy mouse model
2017
Steven Finkbeiner, MD, PhD J. David Gladstone Institute Novel human FTLD neuron and microglia cell models for drug discovery
Thomas Kukar, PhD Emory University Rescue of lysosomal dysfunction, neuroinflammation, and neurodegeneration by lysosomal GRN-2 in a mouse model of PGRN deficiency and Frontotemporal Dementia
2015 - 2017
Xinglong Wang, PhD Case Western Reserve University Mitochondrial TDP-43 as a Novel Therapeutic Target for FTD
Justin Ichida, PhD University of Southern California A novel neuroprotective compound targeting endogenous function of C9ORF72 in vivo
2015
Mari DeMarco, PhD University of British Columbia Quantitation of TDP-43 isoforms in CSF by mass spectroscopy
Edward Huey, MD Columbia University Low-dose lithium for the treatment of behavioral symptoms of FTD
Keith St. Lawrence, PhD Lawson Health Research Institute The role of perfusion MRI in improving the diagnosis of FTD subtypes and longitudinal monitoring of disease progression
2014
Charlotte Teunissen, PhD VU Medical Center in Amsterdam Novel Diagnostic CSF Biomarkers for Pathological Subtypes of FTD
Matthew Disney, PhD The Scripps Research Institute Lead Optimization and Pre-clinical Testing of Small Molecules that Modulate Toxicity of cFTD/ALS
2013
Jeffrey Rothstein, MD, PhD Johns Hopkins University FTD C9ORF72 Based Biomarkers for Antisense-based Drug Discovery Validation
Donald Lo, PhD Duke University Brain slice screen for microRNA-targeted drug lead candidates for tau-associated FTD
2012
Jeffrey Rothstein, MD, PhD Johns Hopkins University Development of antisense therapy and therapeutic biomarker for C9orf72 FTD/ALS mutation patients
Nigel Cairns, FRCPath, PhD Washington University, St. Louis Restoring progranulin in frontotemporal disease
Haung Yu, PhD Columbia University Development of small molecule enhancers of autophagy for the clearance of protein aggregates and treatment of FTD
2011
Adam Boxer, MD, PhD UCSF Biomarker Optimization for Progranulin Trials
William Seeley, MD UCSF Dynamic disease-monitoring network biomarkers for tracking frontotemporal dementia
Charlotte Teunissen, PhD VU University Medical Center Identification of novel discriminatory CSF biomarkers for different FTD subtypes by proteomics
2010
William Hu, MD Emory University CSF Biomarkers of FTLD-TDP and FTLD-Tau — A Multi-Center Study
Allen Roses, MD Duke University Fine-mapping and characterization of genetic biomarkers that facilitate the acceleration of drug discovery for frontotemporal dementias
Marcel Verbeek, PhD, MSc Donders Institute for Brain, Cognition, and Behavior
Radboud University		 TDP-43 and tau as cerebrospinal fluid biomarkers to discriminate frontotemporal dementia subtypes
Victor Villemagne, MD Austin Health [18F]-THK523, a novel in vivo tau imaging agent
2009
Einar Sigurdsson, PhD New York University Passive Immunotherapy for Frontotemporal Dementia
Philip van Damme, MD, PhD KU Leuven Drug Discovery for Progranulin-Mediated Frontotemporal Lobar Degeneration
Haung Yu, PhD Columbia University Tau Clearance by Autophagy
2008
Adam Boxer, MD, PhD UCSF A Pilot Clinical Trial of NAP (AL-108) for Corticobasal Degeneration and Frontotemporal Lobar Degeneration with Predicted Corticobasal Degeneration Pathology
Gabriela Chiosis, PhD Memorial Sloan-Kettering Cancer Center Hsp90 inhibitors in tauopathies: in vivo pre-clinical development
Virginia Y.-M. Lee, PhD University of Pennsylvania Frontotemporal Lobar Degeneration (FTLD) biomarker assays
2007
Ben Bahr, PhD University of North Carolina at Pembroke In vitro testing of new lysosomal modulatory drugs for reducing tau aggregates in a hippocampal slice model
Einar Sigurdsson, PhD New York University Clearance of Pathological Tau Conformers
Tara Spires-Jones, DPhil Massachusetts General Hospital Sirtuins as modifiers of neurodegeneration in a mouse model of frontotemporal dementia
David Vocadlo, PhD Simon Fraser University Optimization of Pharmacokinetic and Pharmacodynamic Properties of a Small Molecule O-glycosylation Inhibitor for Treatment of Frontotemporal Dementia

AFTD-ADDF Diagnostics Accelerator

Name Institution Title
2020
Judith Steen, PhD Harvard Medical School

FTD Biomarkers Initiative

Name Institution Title
2019
Anthony Fitzpatrick, PhD  Columbia University Medical Center Cryo-electron microscopy of brain-derived TDP-43 filaments to rationally design PET ligands for FTD
Leonard Petrucelli, PhD Mayo Clinic Jacksonville Assessing poly(GP) proteins as clinical and pharmacodynamic biomarkers of C9ORF72-associated FTD
Magdalini Polymenidou, PhD University of Zurich, Switzerland Targeting structural alterations of TDP-43 and other proteins to develop biomarkers for FTLD subtypes
2018
Adam Boxer, MD, PhD and Howie Rosen, MD University of California San Francisco Individualized clinical and MRI endpoints for clinical trials in frontotemporal lobar degeneration, a pilot study
Tim Miller, MD, PhD Washington University St. Louis Generation of a PET tracer for TDP-43 aggregates for ALS and FTD
2016
Randall Bateman, MD Washington University in St. Louis Human CNS tau kinetics in tauopathies
Christian Haass, PhD Ludwig-Maximilians University and DZNE Assessing poly(GP) proteins as clinical and pharmacodynamic biomarkers of C9orf72-associated FTD
Leonard Petrucelli, PhD Mayo Clinic – Jacksonville Identification of novel biofluid markers of tau and TDP-43 pathology
Jonathan Rohrer, MD University College London Idenitification of novel biofluid markers of tau & TDP43
Judith Steen, PhD Boston Children's Hospital Using TDP43 as a biomarker in FTD patients

Treat FTD Fund

Name Institution Title
2022
Anne-Marie Li-Kwai-Cheung Wave Life Sciences Wave Life Sciences: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
2017
Barbara Borroni University of Brescia Non-invasive brain stimulation to restore cortical plasticity